Cannabinoids, the active components of marijuana and their endogenous counterparts, exert many of their actions in brain through the seven-transmembrane receptor CB 1 . This receptor is coupled to the activation of the extracellular signal-regulated kinase (ERK) cascade. However, the precise molecular mechanism for CB 1 -mediated ERK activation is still unknown. Here, we show that in U373 MG human astrocytoma cells, CB 1 receptor activation with the cannabinoid agonist ⌬ 8 -tetrahydrocannabinol dimethyl heptyl (HU-210) was coupled to ERK activation and protection from ceramide-induced apoptosis. HU-210-induced ERK activation was inhibited by tyrphostin AG1478 and PP2, widely employed inhibitors of the epidermal growth factor receptor (EGF R ) and the Src family of cytosolic tyrosine kinases, respectively. However, HU-210 stimulation resulted in neither EGF R phosphorylation, Src tyrosine phosphorylation, nor increased Src activity. In addition, dominantnegative forms of both proteins were unable to prevent cannabinoid-induced ERK activation, thus excluding the existence of CB 1 -mediated EGF R transactivation or Src activation. Wortmannin and 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294,002), inhibitors of the phosphatidylinositol 3-kinase (PI3K) signaling pathway, blocked cannabinoid-induced ERK activation. Likewise, HU-210 stimulated the PI3K downstream targets protein kinase B (PKB), as shown by its phosphorylation in Thr 308 and Ser 473 residues, and Raf-1. Moreover, ␤␥ subunit release mimicked ERK and PI3K/PKB activation, suggesting that activation of class IB PI3K mediates cannabinoid action. Pro-survival HU-210 action also required activation of both PI3K and ERK signaling pathways. In conclusion, CB 1 -induced ERK activation was mediated by PI3K IB and this effect may have important consequences in the control of cell death/ survival decision.
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Cannabinoids, the active components of marijuana and their endogenous counterparts exert most of their actions through two well characterized seven-transmembrane receptors designated CB 1 and CB 2 (Matsuda et al., 1990; Munro et al., 1993) . The CB 1 receptor is highly expressed in the central nervous system and is also present in peripheral and extraneural sites (Piomelli et al., 2000; Porter and Felder, 2001) . In contrast, the CB 2 receptor is almost restricted to the immune system. The CB 1 receptor is known to be coupled to inhibition of adenylyl cyclase, inhibition of voltage-dependent Ca 2ϩ channels, and activation of G-protein-regulated inwardly rectifying K ϩ channels (Howlett, 1995; Porter and Felder, 2001) . Besides these well established signal transduction events, novel possibilities have arisen to explain cannabinoid regulation of cell death/ survival decision (Guzmán et al., 2001a,b) . Thus the CB 1 receptor has been shown to regulate different members of the mitogen-activated protein kinase family, such as extracellular signal-regulated kinase (ERK) (Bouaboula et al., 1995; Sánchez et al., 1998) , c-Jun N-terminal kinase (Liu et al., 2000; Rueda et al., 2000) , and p38 Rueda et al., 2000) . The CB 1 receptor can also activate the phosphatidylinositol 3-kinase/protein kinase B (PI3K/PKB) signaling pathway and focal adhesion kinase (Derkinderen et al., 1996; 2001) . In addition, the CB 1 receptor modulates sphingolipid metabolism, leading to increased ceramide levels by either activating sphingomyelin hydrolysis (Sánchez et al., 1998; 2001) or enhancing ceramide synthesis de novo (Gómez del Pulgar et al., 2002) .
A complex variety of mechanisms has been described to explain ERK regulation by seven-transmembrane receptors (reviewed in Gschwind et al., 2001; Marinissen and Gutkind, 2001; Pierce et al., 2001 ). In the case of G i -coupled receptors such as CB 1 , several mechanisms could be hypothesized to mediate ERK activation, including: 1) transactivation of growth factor receptors with intrinsic tyrosine kinase activity (Gschwind et al., 2001) ; 2) ␤-arrestin-mediated receptor internalization and recruiting of cytosolic tyrosine kinases of the Src family (Pierce et al., 2001; Marinissen and Gutkind, 2001) ; 3) G protein-dependent class IB PI3K activation (Lopez-Ilasaca et al., 1997; Marinissen and Gutkind, 2001) . In the present work, we investigated how the CB 1 receptor is coupled to ERK activation and its implications in cannabinoid regulation of glial cell death/survival decision.
405 nm after substrate incubation. In addition, for some experiments, cell viability was determined by Trypan blue exclusion.
Western Blot Analysis. Western blots were performed as described previously . After stimulation, cells were washed with ice-cold phosphate-buffered saline (phosphate-buffered saline; 10 mM NaPi, 150 mM NaCl, pH 7.4) and scraped in lysis buffer consisting of 50 mM Tris-HCl, pH 7.5, 1% (v/v) Triton X-100, 1% (w/v) sodium deoxycholate, 1 mM EDTA, 1 mM EGTA, 50 mM NaF, 10 mM sodium ␤-glycerophosphate, 5 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 0.1% (v/v) 2-mercaptoethanol, 0.5 M microcystin-LR, 17.5 g/ml phenylmethylsulfonyl fluoride, 5 g/ml leupeptin, 2 g/ml aprotinin, 20 g/ml soybean trypsin inhibitor, and 5 g/ml benzamidine. Cell lysates cleared by 15 min of centrifugation at 12,000g were employed for the different experimental procedures. After protein normalization samples were subjected to 10% SDS-PAGE and transferred to polyvinylidene difluoride membranes . EGF R blotting was performed using 8% SDS-PAGE and high-voltage transfer conditions to allow high-molecular weight proteins to be efficiently transferred. After incubation with primary antibodies (1:1000), blots were developed with appropriate horseradish peroxidase-coupled secondary antibodies (1:20,000) and enhanced chemiluminescence detection kit. Loading controls were performed with an anti-␣-tubulin antibody. Densitometric analysis of the luminograms was performed using a GS-700 Imaging Densitometer (Bio-Rad, Hercules, CA) and MultiAnalyst software. Relative values of optical density of the representative experiment shown are included in the figures.
Immunoprecipitation and Src Activity Assay. Cleared cell lysates (500 g protein) were incubated with 2 g of anti-EGF R , Src, or Fyn antibodies precoupled to protein G-Sepharose. After washing with lysis buffer, EGF R and Src phosphorylation status was determined in the immunoprecipitate by Western blot using the PY20 antibody. In addition, Western blot analyses of total cell extracts were performed with an anti-pY1173-EGF R or anti-pY416-Src antibody. For Src activity assays, immunoprecipitated proteins were transferred to Src activity buffer consisting of 100 mM Tris-HCl, pH 7.2, 50 mM magnesium acetate, 10 mM MnCl 2 , 1 mM EGTA, 1 mM sodium orthovanadate, 1 mM dithiothreitol, and 0.5 M microcystin-LR, 17.5 g/ml phenylmethylsulfonyl fluoride, 5 g/ml leupeptin, 2 g/ml aprotinin, 20 g/ml soybean trypsin inhibitor, and 5 g/ml benzamidine. Kinase activity was determined in the presence of 200 M ATP, 5 Ci of [␥Ϫ 32 P]ATP, and 500 M substrate peptide corresponding to amino acids 6 to 20 of p34 cdc2 . Endogenous phosphorylation was also determined in parallel. After 10 min, reactions were stopped with 75 mM orthophosphoric acid, samples were centrifugated, and supernatants spotted on Whatman P81 filter paper (Whatman, Maidstone, UK). Filters were washed and radioactivity was determined by liquid scintillation counting.
Ras Activation. The fusion construct GST-Raf-RBD was overexpressed in E. coli DH5␣ following standard procedures. Cleared cell lysates (250 g of protein) were incubated in the presence of GSTRaf-RBD precoupled to agarose-glutathione complexes (Amersham Biosciences, Little Chalfont, Buckinghamshire, UK) to detect activated Ras GTP . Beads were extensively washed with phosphate-buffered saline and, after SDS-PAGE, immunoblotting was performed using monoclonal anti-pan-Ras antibody (Oncogene, Boston, MA).
Raf-1 Activity. Raf-1 activity assays were performed as described previously . In summary, immunoprecipitated Raf-1 was incubated in kinase buffer in the presence of 1 g of myelin basic protein and [␥Ϫ 32 P]ATP, reactions were stopped with SDS sample buffer and substrate phosphorylation was determined after SDS-PAGE and autoradiography.
Statistical Analysis. Results shown represent the means Ϯ S.D. of the number of experiments indicated in every case. Statistical analysis was performed by analysis of variance. A post hoc analysis was made by the Student-Neuman-Keuls test.
Results

CB 1 -Induced ERK Activation Protects Astrocytoma
Cells from Ceramide-Induced Apoptosis. To elucidate the mechanism of cannabinoid activation of the ERK pathway, we first examined cannabinoid-induced ERK activation in the presence of different pharmacological inhibitors using a monoclonal anti-phospho-Tyr 204 antibody that recognizes phosphorylated ERK. CB 1 stimulation with the cannabinoid agonist HU-210 resulted in a time-dependent ERK activation (data not shown) that peaked at 10 min (Fig. 1A ). This effect was completely prevented by the selective CB 1 antagonist SR141716, thus evidencing the involvement of this receptor. To determine whether transactivation of receptors with intrinsic tyrosine kinase activity such as EGF R or plateletderived growth factor receptor could be responsible for CB 1 -induced ERK activation, we employed inhibitors of tyrosine kinase activity with different selectivity. Tyrphostin AG1478, a selective EGF R inhibitor, but not tyrphostin AG1296, a selective platelet-derived growth factor receptor inhibitor, abrogated HU-210-induced ERK activation (Fig.  1A) . In addition, the pyrazolopyrimidine PP2 and herbimycin A, two inhibitors of the Src family of cytosolic tyrosine kinases, blocked cannabinoid-induced ERK activation (Fig.  1A) . The concentration-dependent action of tyrphostin AG1478 and PP2 on HU-210-induced ERK activation was determined (data not shown), allowing us to calculate IC 50 values of 0.1 and 0.8 M, respectively.
The important role of the mitogenic ERK cascade in the control of cell death/survival decision (Grewal et al., 1999; Kolch, 2000) prompted us to investigate the functional consequences of CB 1 -induced ERK activation in astrocytoma cells. Cells incubated with the permeable ceramide analog C 2 -ceramide underwent apoptosis (Fig. 1B) , and HU-210 inhibited this process. Moreover, exposure to other synthetic cannabinoids, such as CP-55940 and WIN-55,212-2 mimicked the antiapoptotic action of HU-210 (Fig. 1C) . Cannabinoid pro-survival action relied on CB 1 receptor activation, as evidenced by SR141716 antagonism (Fig. 1C) . To investigate the potential involvement of the ERK cascade in CB 1 -mediated protection from apoptosis, we employed the specific mitogen-activated protein kinase kinase inhibitor PD98059. This compound abrogated cannabinoid prosurvival action, thus indicating the involvement of the ERK signaling pathway. Moreover, like cannabinoid-induced ERK activation, cannabinoid prosurvival effect was also inhibited by tyrphostin AG1478. These data show that CB 1 -induced ERK activation is functionally relevant in our experimental model and results in cell protection from apoptosis.
CB 1 -Induced ERK Activation Does Not Involve EGF R Transactivation. Next, we examined whether CB 1 -mediated transactivation of EGF R could be responsible for ERK activation. Although tyrphostin AG1478 prevented HU-210-induced ERK activation (Fig. 1A) , HU-210 was not able to induce EGF R phosphorylation ( Fig. 2A) . Under the same experimental conditions, EGF potently increased tyrosine phosphorylation of immunoprecipitated EGF R , and this effect was indeed blocked by tyrphostin AG1478. Similar results were obtained with an antibody against activated EGF R that specifically recognizes phosphorylated Tyr 1173. HU-210 was ineffective in eliciting EGF R phosphorylation, whereas EGF induced EGF R phosphorylation (Fig. 2B) . The apparent contradiction of the results obtained with tyrphostin AG1478 in ERK activation assays and EGF R phosphorylation experiments required further analysis. Therefore, we stably transfected U373 MG cells with CD533, a truncated form of EGF R that acts as a dominant negative form (Redemann et al., 1992) . CD533-U373 MG cells did not show reduced cannabinoid-induced ERK activation (Fig. 2C ), in line with the lack of involvement of EGF R in HU-210-induced ERK activation. In contrast, EGF-induced EGF R phosphorylation was effectively abrogated (Fig. 2D) , evidencing the effectiveness of the stably generated CD533-U373 MG cells to block EGF signaling. In addition, BB94, an inhibitor of zinc-dependent metalloproteinases responsible for proheparin binding-EGF shedding required for G-protein-coupled receptor transactivation of EGF R (Prenzel et al., 1999) , did not prevent HU-210-induced ERK activation (data not shown), supporting the absence of CB 1 -mediated EGF R transactivation.
Lack of Involvement of Src Tyrosine Kinases in CB 1 -Induced ERK Activation. To investigate the potential involvement of the Src family of tyrosine kinases in CB 1 signaling, kinase activity assays were performed. Immunoprecipitation from U373 MG cell extracts of Src, Fyn, and Yes using an anti-pan Src antibody did not reveal any increased activity of those kinases by HU-210 stimulation, whereas under the same conditions, PDGF induced a robust Src activation (Fig. 3A) . Moreover, time course analysis from 5 to 60 min did not evidence stimulation of pan-Src activity by HU-210 (data not shown). As cannabinoid-induced focal adhesion kinase regulation in hippocampal neurons has been proposed to be specifically mediated by Fyn (Derkinderen et al., 2001) , we examined Fyn kinase activity using a specific antibody against this protein. However, no changes in Fyn activity could be detected (Fig. 3A) .
To fully address the question of cannabinoid regulation of Src, we have also analyzed its phosphorylation status. Immunoprecipitation with anti-PY20 antibody and subsequent detection with the Src antibody revealed an increased global tyrosine phosphorylation of Src induced by PDGF but not HU-210 (Fig. 3B) (Fig. 3B) . Moreover, enforced expression of dominant negative Src-K295R did not affect HU-210-induced ERK activation (Fig. 3C) , whereas it efficiently blocked PDGF stimulation of Src activity (data not shown) because of its overexpression in transfected cells (Fig. 3D) .
Involvement of the PI3K/PKB Pathway in CB 1 -Induced ERK Activation and Cell Survival. Because G protein ␤␥ subunit release may activate class IB PI3K leading to ERK activation (Lopez-Ilasaca et al., 1997; Marinissen and Gutkind, 2001 ), we examined whether this process occurred upon CB 1 activation by employing wortmannin and LY294,002, two PI3K inhibitors. As shown in Fig. 4A , HU-210-induced ERK activation was completely abrogated by PI3K inhibition. Moreover, mastoparan-induced G protein ␤␥ subunit release led to ERK activation, and such effect was not additive to HU-210 action (Fig. 4A) . Support for the involvement of the PI3K signaling pathway was obtained by showing that its primary downstream target PKB was regulated in a similar manner. Phosphorylation of PKB occurs in different residues that represent progressive steps in its activation mechanism (Brazil and Hemmings, 2001 ). Thus, HU-210 challenge induced PKB Thr 308 phosphorylation (Fig. 4B) , which reflects PI3K/PDK1-mediated phosphorylation. HU-210 also induced PKB Ser 473 phosphorylation (Fig.  4B) , indicative of the last activation step upon PI3K stimulation. Phosphorylation of both residues was antagonized by SR141716, pointing to the involvement of CB 1 receptor. In addition, PI3K inhibition by wortmannin and LY294,002 abrogated HU-210-induced phosphorylation of both PKB residues and therefore validated ERK data obtained with these inhibitors. Moreover, mastoparan-induced ␤␥ subunit release increased PKB phosphorylation in both residues, and this effect was not additive to that of HU-210 (Fig. 4B) . We next determined whether Ras was involved in ERK activation given that PI3K-dependent ERK activation might be mediated by this monomeric G protein (Lopez-Ilasaca et al., 1997) . However, HU-210 stimulation did not induce Ras activation in U373 MG cells (Fig. 4C ), pointing to a PI3K-dependent mechanism of ERK activation that does not involve Ras activation. A similar mechanism has been proposed for PI3K activation of the ERK cascade by direct PAK-mediated Raf-1 phosphorylation (King et al., 1998; Chaudhary et al., 2000; Zang et al., 2001 ). Likewise, CB 1 receptor activation enhances Raf-1 activity in U373 MG cells (Fig. 4D) , similarly to what occurs in primary astrocytes (Sá nchez et al., 1998) and C6 glioma cells .
Confirmation of the functional relevance of PI3K-dependent ERK activation was investigated in the U373 MG cell model of cannabinoid anti-apoptotic action. Cannabinoid-mediated protection from ceramide-induced cell death was abrogated by wortmannin and LY294,002 (Fig. 4E) . Thus, cannabinoids exert an effective pro-survival action because of their ability to activate in a concerted manner the classical Fig. 2 . CB 1 -induced ERK activation does not involve EGF R transactivation. O.D., optical density. A, after stimulation with 50 nM HU-210 or 100 ng/ml EGF in the absence or presence of 1 M tyrphostin AG1478, U373 MG cell extracts were immunoprecipitated (IP) with an anti-EGF R antibody and Western blot (WB) was performed using anti-phosphotyrosine PY20 antibody. B, cell lysates from stimulated cells were subjected to Western blot analysis using an anti-phospho-Tyr-1173-EGF R antibody. 
Discussion
Results presented herein show that CB 1 receptor coupling to ERK activation depends on Gi protein dissociation and subsequent PI3K IB activation. Although many G proteincoupled receptors activate different members of the mitogenactivated protein kinase family by transactivation of tyrosine kinase receptors (Gschwind et al., 2001) , CB 1 -mediated activation of ERK occurs by an EGF R -independent mechanism. In addition, seven-transmembrane receptors have been shown to recruit Src family members during the ␤-arrestinmediated internalization process, which in certain cases is coupled to ERK activation (Marinissen and Gutkind, 2001; Pierce et al., 2001) . Regarding the CB 1 receptor, our results exclude the involvement of the Src family of cytosolic tyrosine kinases in ERK activation, in line with data showing that internalization-defective CB 1 receptors exhibit correct ERK activation capacity (Roche et al., 1999) .
As previously highlighted by others (e.g., Davies et al., 2000) , the study of cannabinoid-induced ERK activation has taught us the necessity for caution when interpreting data obtained using pharmacological inhibitors claimed in the literature to be highly selective. Thus, whereas experiments conducted with pharmacological inhibitors suggested the involvement of certain mechanism for CB 1 -mediated ERK activation, detailed study of such pathways (EGF R transactivation or Src involvement) was fruitless and pointed in different directions. It should be noted that the IC 50 values for AG1478 and PP2 action obtained in this study (0.1 and 0.8 M, respectively) indicate that the concentrations employed (1 and 10 M) are high enough to inhibit the desired target (EGF R and Src) but not so massive as to explain the nonspecific actions observed. The existence of potential targets for tyrphostins different from the paradigmatic ones can be exemplified by tyrphostin AG213, which, although claimed to be specific for the EGF R , also exerts complex actions on the EGF-ERK signaling pathway (Levitzki, 1999) . Paradoxical stimulation of the ERK pathway by tyrphostins has been described and attributed to a potential inhibitory effect on tyrosine phosphatase activity (Nowak et al., 1997) . In addition, different tyrphostins (AG213, AG34, and AG82) have been shown to alter Src-initiated signaling and cellular transformation, as well as to inhibit Bcr-Abl tyrosine kinase (Agbotounou et al., 1994; Levitzki, 1999) . Moreover, in astrocytes, tyrphostin AG1478 was able to prevent thrombin-induced ERK activation, but EGF R transactivation could not be evidenced (Wang et al., 2002) . Like quinoline-derived tyrphostins, pyrazolopirimidine-derived inhibitors of the Src family, such as PP2, act as ATP binding competitors. In this regard, interference of both types of inhibitors toward unrelated postulated targets has been described. Thus, in certain cases, tyrphostins may inhibit Src family-mediated actions (Agbotounou et al., 1994; Levitzki, 1999) and pyrazolopirimidines may inhibit tyrosine kinase receptors (Susa et al., 2000) .
Our results highlight the existence of cannabinoid-induced activation of survival signaling pathways in a coordinated manner. Thus, CB 1 activation results in PI3K/PKB stimulation (Gómez del Pulgar et al., 2000; this study) in concert with the ERK pathway (Guzmá n et al., 2001b ; this study). The important role of the mitogenic ERK cascade (Grewal et al., 1999; Kolch, 2000) as well as of the anti-apoptotic PI3K/ PKB pathway (Brazil and Hemmings, 2001) in the control of the cell death/survival decision is well known. In general, activation of these signaling pathways leads to cell protection from death stimuli by acting either independently or coordinately. Thus, CB 1 -mediated acute ERK and PI3K/PKB activation protects glial cells from ceramide induction of the apoptotic program. On the other hand, CB 1 -activation can also promote apoptosis, particularly in transformed cells, owing to its ability to induce sustained ceramide generation and ERK activation Guzmá n et al., 2001b) . In fact, recent research has evidenced growth arrest and deleterious actions of the ERK pathway when activated in a sustained manner. For example, sustained ERK activation is in part responsible for neural cell death after brain ischemia or glutamate excitotoxicity (Alessandrini et al., 1999) . Similarly, in PC12 neuronal-like cells, whereas short-term ERK activation promotes proliferation, sustained ERK activation results in cell cycle arrest and neuronal differentiation (Grewal et al., 1999) . Regarding glial cells, different magnitude and kinetics of CB 1 -induced ERK activation produces opposite cellular outcomes (Guzmá n et al., 2001a). Thus, whereas short-term ERK activation protects glial cells from ceramide-induced apoptosis (this study), sustained ERK activation promotes apoptosis or growth arrest Fanton et al., 2001) . Current research in our laboratory focuses on the identification of the downstream targets of these signaling pathways that would be ultimately responsible for CB 1 -mediated cell protection or death.
